Population pharmacokinetics of ravidasvir in adults with chronic hepatitis C virus infection and impact of antiretroviral treatment
Antimicrob Agents Chemother. 2024 May 20:e0000824. doi: 10.1128/aac.00008-24. Online ahead of print.ABSTRACTRavidasvir (RDV) is a novel NS5A inhibitor that exhibits potent pan-genotypic inhibition of hepatitis C virus (HCV) replication. Sofosbuvir (SOF) plus RDV was demonstrated to be efficacious and safe in adults with active HCV infection, including those living with HIV (LWHIV), in the STORM-C-1 trial. We assessed the population pharmacokinetics (PK) of RDV in a sub-study nested within STORM-C-1 conducted in Thailand and Malaysia. SOF (400 mg) plus RDV (200 mg) was administered orally once daily for 12 weeks to adults w...
Source: Antimicrobial Agents and Chemotherapy - May 20, 2024 Category: Microbiology Authors: Navarat Panjasawatwong Anchalee Avihingsanon Caroline Men étrey Isabela Ribeiro Nicolas Salvadori Alistair Swanson Jean-Yves Gillon Soek-Siam Tan Sombat Thanprasertsuk Satawat Thongsawat Tim R Cressey STORM-C-1 study team Source Type: research

Dual β-lactam for treatment of pulmonary < em > Mycobacterium abscessus < /em > in a child
Antimicrob Agents Chemother. 2024 May 17:e0031924. doi: 10.1128/aac.00319-24. Online ahead of print.ABSTRACTTreatment of Mycobacterium abscessus infection presents significant challenges, exacerbated by the emergence of macrolide-resistant strains that necessitate the use of multiple antimicrobials in combination and carry the potential for significant toxic effects. Select dual beta-lactam combinations, with or without beta-lactamase inhibitors, have been shown to be highly active in vitro. Herein, we describe a 6-year-old child with underlying mild bilateral lower lobe cylindrical bronchiectatic lung disease who develope...
Source: Antimicrobial Agents and Chemotherapy - May 17, 2024 Category: Microbiology Authors: Bradford Becken Khalid M Dousa John L Johnson Steven M Holland Robert A Bonomo Source Type: research

Phase 1 drug-drug interaction study to assess the effect of CYP3A4 inhibition and pan-CYP induction on the pharmacokinetics and safety of fosmanogepix in healthy participants
This study is registered with ClinicalTrials.gov as NCT04166669 and with EudraCT as number 2019-003586-17.PMID:38757982 | DOI:10.1128/aac.01650-23 (Source: Antimicrobial Agents and Chemotherapy)
Source: Antimicrobial Agents and Chemotherapy - May 17, 2024 Category: Microbiology Authors: Michael R Hodges Sjoerd van Marle William G Kramer Eric Ople Margaret Tawadrous Abhijeet Jakate Source Type: research

Phenotypic amikacin resistance may not indicate poor response to amikacin in < em > Mycobacterium avium < /em > complex pulmonary disease
Antimicrob Agents Chemother. 2024 May 17:e0008424. doi: 10.1128/aac.00084-24. Online ahead of print.ABSTRACTWhen using amikacin to treat Mycobacterium avium complex pulmonary disease (MAC-PD), a minimum inhibitory concentration resistance breakpoint of ≥64 mcg/mL is recommended. We explored whether amikacin resistance characterized by phenotypic drug susceptibility testing was associated with clinical outcomes or mutational resistance in a retrospective cohort of patients with MAC-PD. Despite little aminoglycoside exposure, amikacin resistance was common in our MAC-PD patients but was not associated with worse outcomes o...
Source: Antimicrobial Agents and Chemotherapy - May 17, 2024 Category: Microbiology Authors: L M Minuk S K Brode M Mehrabi M K Sharma M Stobart H Soualhine T K Marras Source Type: research

Dual β-lactam for treatment of pulmonary < em > Mycobacterium abscessus < /em > in a child
Antimicrob Agents Chemother. 2024 May 17:e0031924. doi: 10.1128/aac.00319-24. Online ahead of print.ABSTRACTTreatment of Mycobacterium abscessus infection presents significant challenges, exacerbated by the emergence of macrolide-resistant strains that necessitate the use of multiple antimicrobials in combination and carry the potential for significant toxic effects. Select dual beta-lactam combinations, with or without beta-lactamase inhibitors, have been shown to be highly active in vitro. Herein, we describe a 6-year-old child with underlying mild bilateral lower lobe cylindrical bronchiectatic lung disease who develope...
Source: Antimicrobial Agents and Chemotherapy - May 17, 2024 Category: Microbiology Authors: Bradford Becken Khalid M Dousa John L Johnson Steven M Holland Robert A Bonomo Source Type: research

Phase 1 drug-drug interaction study to assess the effect of CYP3A4 inhibition and pan-CYP induction on the pharmacokinetics and safety of fosmanogepix in healthy participants
This study is registered with ClinicalTrials.gov as NCT04166669 and with EudraCT as number 2019-003586-17.PMID:38757982 | DOI:10.1128/aac.01650-23 (Source: Antimicrobial Agents and Chemotherapy)
Source: Antimicrobial Agents and Chemotherapy - May 17, 2024 Category: Microbiology Authors: Michael R Hodges Sjoerd van Marle William G Kramer Eric Ople Margaret Tawadrous Abhijeet Jakate Source Type: research

Phenotypic amikacin resistance may not indicate poor response to amikacin in < em > Mycobacterium avium < /em > complex pulmonary disease
Antimicrob Agents Chemother. 2024 May 17:e0008424. doi: 10.1128/aac.00084-24. Online ahead of print.ABSTRACTWhen using amikacin to treat Mycobacterium avium complex pulmonary disease (MAC-PD), a minimum inhibitory concentration resistance breakpoint of ≥64 mcg/mL is recommended. We explored whether amikacin resistance characterized by phenotypic drug susceptibility testing was associated with clinical outcomes or mutational resistance in a retrospective cohort of patients with MAC-PD. Despite little aminoglycoside exposure, amikacin resistance was common in our MAC-PD patients but was not associated with worse outcomes o...
Source: Antimicrobial Agents and Chemotherapy - May 17, 2024 Category: Microbiology Authors: L M Minuk S K Brode M Mehrabi M K Sharma M Stobart H Soualhine T K Marras Source Type: research

Dual β-lactam for treatment of pulmonary < em > Mycobacterium abscessus < /em > in a child
Antimicrob Agents Chemother. 2024 May 17:e0031924. doi: 10.1128/aac.00319-24. Online ahead of print.ABSTRACTTreatment of Mycobacterium abscessus infection presents significant challenges, exacerbated by the emergence of macrolide-resistant strains that necessitate the use of multiple antimicrobials in combination and carry the potential for significant toxic effects. Select dual beta-lactam combinations, with or without beta-lactamase inhibitors, have been shown to be highly active in vitro. Herein, we describe a 6-year-old child with underlying mild bilateral lower lobe cylindrical bronchiectatic lung disease who develope...
Source: Antimicrobial Agents and Chemotherapy - May 17, 2024 Category: Microbiology Authors: Bradford Becken Khalid M Dousa John L Johnson Steven M Holland Robert A Bonomo Source Type: research

Phase 1 drug-drug interaction study to assess the effect of CYP3A4 inhibition and pan-CYP induction on the pharmacokinetics and safety of fosmanogepix in healthy participants
This study is registered with ClinicalTrials.gov as NCT04166669 and with EudraCT as number 2019-003586-17.PMID:38757982 | DOI:10.1128/aac.01650-23 (Source: Antimicrobial Agents and Chemotherapy)
Source: Antimicrobial Agents and Chemotherapy - May 17, 2024 Category: Microbiology Authors: Michael R Hodges Sjoerd van Marle William G Kramer Eric Ople Margaret Tawadrous Abhijeet Jakate Source Type: research

Phenotypic amikacin resistance may not indicate poor response to amikacin in < em > Mycobacterium avium < /em > complex pulmonary disease
Antimicrob Agents Chemother. 2024 May 17:e0008424. doi: 10.1128/aac.00084-24. Online ahead of print.ABSTRACTWhen using amikacin to treat Mycobacterium avium complex pulmonary disease (MAC-PD), a minimum inhibitory concentration resistance breakpoint of ≥64 mcg/mL is recommended. We explored whether amikacin resistance characterized by phenotypic drug susceptibility testing was associated with clinical outcomes or mutational resistance in a retrospective cohort of patients with MAC-PD. Despite little aminoglycoside exposure, amikacin resistance was common in our MAC-PD patients but was not associated with worse outcomes o...
Source: Antimicrobial Agents and Chemotherapy - May 17, 2024 Category: Microbiology Authors: L M Minuk S K Brode M Mehrabi M K Sharma M Stobart H Soualhine T K Marras Source Type: research

Dual β-lactam for treatment of pulmonary < em > Mycobacterium abscessus < /em > in a child
Antimicrob Agents Chemother. 2024 May 17:e0031924. doi: 10.1128/aac.00319-24. Online ahead of print.ABSTRACTTreatment of Mycobacterium abscessus infection presents significant challenges, exacerbated by the emergence of macrolide-resistant strains that necessitate the use of multiple antimicrobials in combination and carry the potential for significant toxic effects. Select dual beta-lactam combinations, with or without beta-lactamase inhibitors, have been shown to be highly active in vitro. Herein, we describe a 6-year-old child with underlying mild bilateral lower lobe cylindrical bronchiectatic lung disease who develope...
Source: Antimicrobial Agents and Chemotherapy - May 17, 2024 Category: Microbiology Authors: Bradford Becken Khalid M Dousa John L Johnson Steven M Holland Robert A Bonomo Source Type: research

Phase 1 drug-drug interaction study to assess the effect of CYP3A4 inhibition and pan-CYP induction on the pharmacokinetics and safety of fosmanogepix in healthy participants
This study is registered with ClinicalTrials.gov as NCT04166669 and with EudraCT as number 2019-003586-17.PMID:38757982 | DOI:10.1128/aac.01650-23 (Source: Antimicrobial Agents and Chemotherapy)
Source: Antimicrobial Agents and Chemotherapy - May 17, 2024 Category: Microbiology Authors: Michael R Hodges Sjoerd van Marle William G Kramer Eric Ople Margaret Tawadrous Abhijeet Jakate Source Type: research

Phenotypic amikacin resistance may not indicate poor response to amikacin in < em > Mycobacterium avium < /em > complex pulmonary disease
Antimicrob Agents Chemother. 2024 May 17:e0008424. doi: 10.1128/aac.00084-24. Online ahead of print.ABSTRACTWhen using amikacin to treat Mycobacterium avium complex pulmonary disease (MAC-PD), a minimum inhibitory concentration resistance breakpoint of ≥64 mcg/mL is recommended. We explored whether amikacin resistance characterized by phenotypic drug susceptibility testing was associated with clinical outcomes or mutational resistance in a retrospective cohort of patients with MAC-PD. Despite little aminoglycoside exposure, amikacin resistance was common in our MAC-PD patients but was not associated with worse outcomes o...
Source: Antimicrobial Agents and Chemotherapy - May 17, 2024 Category: Microbiology Authors: L M Minuk S K Brode M Mehrabi M K Sharma M Stobart H Soualhine T K Marras Source Type: research

High potency of linalool-zinc oxide nanocomposite as a new agent for cystic echinococcosis treatment
Antimicrob Agents Chemother. 2024 May 16:e0173423. doi: 10.1128/aac.01734-23. Online ahead of print.ABSTRACTThis current in vitro, ex vivo, and in vivo research aims to evaluate and analyze the linalool-zinc oxide nanocomposite (Lin-ZNP) for treating cystic echinococcosis. Lin-ZNP was synthesized using an ethanolic solution of polyvinyl alcohol. The protoscolicidal effects of Lin-ZNP were tested on hydatid cyst protoscoleces (PTS) in both in vitro and ex vivo by eosin exclusion test. The study also examined the impact on caspase-3 gene expression and the external structure of PTS. The in vivo effect was measured by examini...
Source: Antimicrobial Agents and Chemotherapy - May 16, 2024 Category: Microbiology Authors: Aishah E Albalawi Abdullah F Shater Abdullah D Alanazi Muslimah N Alsulami Hamdan I Almohammed Source Type: research

Gentamicin concentration and acute kidney injury in term neonates treated for neonatal sepsis with gentamicin and ampicillin-cloxacillin combination
Antimicrob Agents Chemother. 2024 May 15:e0149523. doi: 10.1128/aac.01495-23. Online ahead of print.ABSTRACTGentamicin is widely used to treat neonatal infections caused by both Gram-negative and Gram-positive bacteria, and the WHO recommends its use while monitoring serum creatinine and gentamicin concentrations to avoid drug-induced nephrotoxicity and ototoxicity. Yet in some resource-limited settings, the drug is used without monitoring. A population pharmacokinetics study involving term neonates with neonatal infection admitted to a neonatal unit. Participants were started on intravenous gentamicin 5 mg/kg once a day i...
Source: Antimicrobial Agents and Chemotherapy - May 15, 2024 Category: Microbiology Authors: Masanyiwa Ernest James Helga Naburi Sabina Mugusi Peter P Kunambi Tosi Mwakyandile Rajabu Hussein Mnkugwe Mohamed Ally Khalfan Mainen J Moshi Omary M Minzi Philip Sasi Source Type: research